MET (Ab-1234) Antibody

What is MET (Ab-1234) Antibody and what epitope does it recognize?

MET (Ab-1234) Antibody is a rabbit polyclonal antibody that specifically recognizes the region around the tyrosine 1234 phosphorylation site of the MET receptor (also known as hepatocyte growth factor receptor or c-Met). The antibody is raised against a synthesized non-phosphopeptide derived from human Met with the sequence K-E-Y(p)-Y-S, corresponding to the area surrounding the tyrosine 1234 phosphorylation site . This antibody is designed to detect endogenous levels of total MET protein, making it valuable for studying MET signaling pathways.

What are the validated applications for MET (Ab-1234) Antibody?

The MET (Ab-1234) Antibody has been primarily validated for Western Blotting (WB) applications . While ELISA has also been reported as a potential application , the antibody's primary strength lies in protein detection via immunoblotting techniques. The recommended dilution for Western Blot applications ranges from 1:500 to 1:3000, though optimal concentrations should be determined empirically for each experimental system .

What is the proper storage condition for maintaining MET (Ab-1234) Antibody activity?

For optimal preservation of antibody activity, MET (Ab-1234) Antibody should be stored at -20°C or -80°C . The antibody is typically supplied in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol . Repeated freeze-thaw cycles should be avoided to prevent degradation of the antibody. For long-term storage, aliquoting the antibody upon receipt is recommended to minimize freeze-thaw cycles.

How can researchers differentiate between phosphorylated and non-phosphorylated forms of MET in experimental systems?

While MET (Ab-1234) Antibody detects total MET protein regardless of phosphorylation status, researchers interested in specifically studying the activation state of MET should consider using phospho-specific antibodies targeting Y1234/Y1235 . Experimental approaches to differentiate between phosphorylated and non-phosphorylated forms include:

• Parallel Western blots with both total MET antibody and phospho-specific antibodies

• Immunoprecipitation with one antibody followed by immunoblotting with the other

• Phosphatase treatment of cell lysates as a control to confirm phospho-specificity

• Stimulation experiments with HGF to induce phosphorylation compared to non-stimulated controls

Scientific data demonstrates that phospho-MET (Y1234/Y1235) can be effectively detected in pervanadate-treated cells (e.g., MDA-MB-468 human breast cancer cell line) compared to untreated controls . Immunofluorescence studies also show that phospho-MET antibodies selectively stain HGF-stimulated cells but not non-stimulated cells .

What are the optimal experimental conditions for detecting MET using Ab-1234 in Western blot applications?

For optimal Western blot detection of MET using Ab-1234 antibody, the following methodological considerations are recommended:

• Sample Preparation:

  • Lyse cells in buffers containing phosphatase inhibitors (especially when studying phosphorylation)

  • Use reduced protein loading (30-50 μg/lane) to minimize background

  • Denature samples at 95°C for 5 minutes in reducing sample buffer

• Electrophoresis and Transfer Conditions:

  • Use 7.5% or 4-15% gradient SDS-PAGE gels due to the relatively large size of MET (~145 kDa)

  • Perform wet transfer at 30V overnight at 4°C for efficient transfer of high molecular weight proteins

• Antibody Incubation:

  • Block membranes with 5% non-fat dry milk or BSA in TBST

  • Use MET (Ab-1234) Antibody at a starting dilution of 1:1000

  • Incubate with primary antibody overnight at 4°C

  • Use appropriate HRP-conjugated secondary antibody (anti-rabbit IgG)

• Detection:

  • Use enhanced chemiluminescence (ECL) detection systems

  • Expected band size for MET is approximately 145 kDa

These conditions should be optimized based on the specific experimental system and cell types being studied.

How can researchers address potential cross-reactivity or non-specific binding issues with MET (Ab-1234) Antibody?

Cross-reactivity and non-specific binding can compromise experimental results. To address these issues:

• Validation Controls:

  • Include MET-knockout or MET-depleted (siRNA) samples as negative controls

  • Use competitive blocking with immunizing peptide to confirm specificity

  • Include positive control samples with known MET expression (e.g., MDA-MB-468 cells)

• Optimization Strategies:

  • Titrate antibody concentration to determine optimal signal-to-noise ratio

  • Adjust blocking conditions (try different blocking agents such as BSA vs. milk)

  • Increase washing stringency with higher salt concentration or mild detergents

  • Pre-adsorb the antibody with non-relevant proteins

• Technical Considerations:

  • For immunofluorescence applications, include secondary-only controls

  • For immunoprecipitation studies, include isotype control antibodies

  • When possible, confirm results with an alternative MET antibody targeting a different epitope

What experimental approaches can be used to study MET signaling pathway activation using MET (Ab-1234) Antibody?

MET signaling can be studied using complementary experimental approaches:

• Stimulation Experiments:

  • Treat cells with HGF (typically 20-100 ng/mL) for 5-30 minutes

  • Monitor time-dependent changes in MET phosphorylation and downstream signaling

  • Use pervanadate (PV) treatment (100 μM for 10 minutes) as a positive control for tyrosine phosphorylation

• Downstream Signaling Analysis:

  • After detecting MET activation, probe for downstream targets:

    • PI3K/AKT pathway (phospho-AKT)

    • RAS/ERK pathway (phospho-ERK)

    • STAT3 pathway (phospho-STAT3)

    • PLCG1 activation

• MET Inhibitor Studies:

  • Combine with selective MET inhibitors to confirm specificity of observed effects

  • Monitor dose-dependent inhibition of MET phosphorylation using both total and phospho-specific antibodies

• Co-Immunoprecipitation:

  • Use MET (Ab-1234) Antibody for immunoprecipitation followed by detection of associated proteins

  • Identify interaction partners of MET following HGF stimulation

What are common troubleshooting strategies for weak or absent signals when using MET (Ab-1234) Antibody?

When experiencing weak or absent signals in Western blot applications:

• Sample Preparation Issues:

  • Ensure sufficient protein is loaded (start with 50-75 μg per lane)

  • Verify sample integrity by checking housekeeping proteins

  • Add fresh protease and phosphatase inhibitors to lysis buffers

  • Avoid excessive heating which may cause protein aggregation

• Detection Sensitivity:

  • Increase antibody concentration (try 1:500 dilution)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use more sensitive detection reagents (e.g., femto-level ECL substrates)

  • Increase exposure time initially to detect weak signals

• Technical Parameters:

  • Optimize transfer conditions for high molecular weight proteins

  • Verify transfer efficiency with reversible protein stains

  • Use PVDF membranes which may provide better protein retention than nitrocellulose

  • Ensure secondary antibody is compatible with primary antibody species (anti-rabbit)

• Experimental Design:

  • Include positive control samples with known MET expression

  • Consider using cells treated with HGF or pervanadate to increase phosphorylation levels

How can researchers distinguish between MET splice variants or proteolytic fragments using MET (Ab-1234) Antibody?

MET can exist in multiple forms, including the full-length precursor (~170 kDa), mature form (~145 kDa), and various proteolytic fragments. To distinguish between these forms:

• Gel Electrophoresis Conditions:

  • Use lower percentage gels (6-8%) for better separation of high molecular weight forms

  • Consider longer run times to achieve better resolution between closely migrating forms

  • Use gradient gels (4-15%) to simultaneously detect fragments of different sizes

• Data Interpretation:

  • Full-length mature MET typically appears as a ~145 kDa band

  • The α-chain (~50 kDa) may be detected if the epitope is within this region

  • The β-chain (~145 kDa) contains the intracellular tyrosine kinase domain including Y1234

  • Proteolytic fragments may appear as lower molecular weight bands

• Validation Approaches:

  • Compare with antibodies targeting different MET domains

  • Use recombinant expression of specific MET variants as controls

  • Perform peptide competition assays to confirm band identity

What methodological considerations are important when comparing MET expression across different cell types or tissue samples?

When conducting comparative studies of MET expression:

• Sample Normalization:

  • Carefully quantify and equalize total protein loading across samples

  • Include multiple housekeeping proteins as loading controls

  • Consider normalizing to total protein (using stain-free technology or Ponceau S)

  • Calculate relative expression using densitometry with appropriate normalization

• Experimental Controls:

  • Include positive control samples with known MET expression

  • Process all samples simultaneously under identical conditions

  • Use the same antibody lot for all experiments in a comparative study

  • Consider running a standard curve with recombinant MET protein

• Technical Considerations:

  • Be aware that different cell lysis methods may extract MET with varying efficiency

  • Consider that membrane proteins like MET may require specialized extraction buffers

  • Account for post-translational modifications that may affect antibody recognition

  • Remember that different tissues may contain varying levels of proteases that could affect MET integrity

How can MET (Ab-1234) Antibody be incorporated into multiplexed detection systems for comprehensive signaling pathway analysis?

Integrating MET detection into multiplexed experimental approaches requires careful planning:

• Multi-Color Western Blotting:

  • Strip and reprobe membranes for different signaling components

  • Use fluorescently-labeled secondary antibodies with spectrally distinct fluorophores

  • Separate proteins with similar molecular weights on different membranes

  • Consider using antibodies from different host species to allow simultaneous probing

• Phosphorylation Profiling:

  • Combine total MET detection with phospho-specific antibodies targeting different residues

  • Monitor multiple downstream pathways in parallel (PI3K/AKT, MAPK, STAT3, etc.)

  • Use phospho-protein arrays to screen for activation of multiple pathways simultaneously

• Multi-Parameter Flow Cytometry:

  • Combine surface MET detection with intracellular phospho-protein staining

  • Perform cell cycle analysis in conjunction with MET signaling assessment

  • Correlate MET expression with functional cellular readouts

• Imaging-Based Approaches:

  • Perform co-localization studies with MET and interacting proteins

  • Use proximity ligation assays (PLA) to detect protein-protein interactions involving MET

  • Combine with fluorescent HGF to monitor ligand-receptor interactions

What experimental design strategies should be considered when studying MET phosphorylation dynamics and inhibitor responses?

When investigating MET phosphorylation dynamics and inhibitor responses:

• Time-Course Experiments:

  • Monitor both rapid (minutes) and sustained (hours) phosphorylation changes

  • Include appropriate time points to capture transient signaling events

  • Collect samples at consistent time points across experimental conditions

• Dose-Response Studies:

  • Use a wide range of HGF concentrations (typically 1-100 ng/mL)

  • For inhibitors, test concentrations spanning at least 3 orders of magnitude

  • Plot dose-response curves to determine EC50/IC50 values

• Combination Studies:

  • Test MET inhibitors in combination with inhibitors of parallel or downstream pathways

  • Analyze synergistic or antagonistic effects using appropriate statistical methods

  • Consider the temporal sequence of drug administration

• Resistance Mechanisms:

  • Develop resistant cell models through prolonged exposure to MET inhibitors

  • Compare MET phosphorylation patterns between sensitive and resistant cells

  • Investigate alternative signaling pathways that may compensate for MET inhibition

How can researchers quantitatively analyze and interpret Western blot data generated using MET (Ab-1234) Antibody?

Quantitative analysis of Western blot data requires rigorous methodology:

• Image Acquisition:

  • Capture images within the linear dynamic range of the detection system

  • Avoid saturated pixels which compromise quantitation

  • Include a standard curve when absolute quantification is required

• Densitometric Analysis:

  • Use appropriate software (ImageJ, Image Studio, etc.) for band quantification

  • Define consistent region-of-interest (ROI) dimensions across all lanes

  • Subtract local background for each measurement

  • Normalize to appropriate loading controls or total protein

• Statistical Analysis:

  • Perform experiments with sufficient biological replicates (minimum n=3)

  • Apply appropriate statistical tests based on data distribution

  • Consider using ANOVA with post-hoc tests for multiple comparisons

  • Report both statistical significance and effect size

• Data Visualization:

  • Present both representative blot images and quantitative graphs

  • Include error bars representing standard deviation or standard error

  • Clearly indicate statistical significance levels

  • Consider using heatmaps for time-course or multi-parameter data

How might MET (Ab-1234) Antibody be utilized in emerging single-cell analysis technologies?

MET (Ab-1234) Antibody could be adapted for use in evolving single-cell methodologies:

• Single-Cell Western Blotting:

  • Optimize antibody concentrations for microfluidic-based single-cell Western platforms

  • Develop multiplexed protocols combining MET with other signaling molecules

  • Correlate MET expression/activation with cellular phenotypes at single-cell resolution

• Mass Cytometry (CyTOF):

  • Conjugate MET antibodies with metal isotopes for mass cytometry

  • Develop panels combining MET detection with 30+ additional markers

  • Apply to heterogeneous tumor samples to identify distinct cellular subpopulations

• Spatial Transcriptomics Integration:

  • Combine antibody-based MET protein detection with spatial transcriptomics

  • Correlate protein expression with mRNA levels at single-cell resolution

  • Map MET activation patterns within the tissue microenvironment

• Live-Cell Imaging Applications:

  • Develop non-disruptive labeling strategies based on MET antibody fragments

  • Monitor real-time changes in MET localization and clustering

  • Correlate with functional cellular responses at single-cell level

What are the key considerations for validating novel MET-targeted therapeutics using MET (Ab-1234) Antibody?

When utilizing MET (Ab-1234) Antibody in therapeutic development:

• Mechanism-of-Action Studies:

  • Determine whether candidates affect total MET levels or phosphorylation status

  • Investigate effects on MET dimerization, internalization, and degradation

  • Assess impact on downstream signaling pathway activation

• Resistance Mechanism Investigation:

  • Monitor changes in MET expression/phosphorylation during treatment resistance development

  • Identify compensatory signaling pathways activated upon MET inhibition

  • Develop rational combination strategies based on observed resistance mechanisms

• Biomarker Development:

  • Correlate baseline MET expression/activation with treatment response

  • Develop quantitative assays for patient stratification

  • Identify threshold levels of MET activation predictive of therapeutic response

• Translational Research:

  • Compare antibody performance across preclinical models and patient samples

  • Develop standardized protocols for clinical biomarker assessment

  • Validate antibody specificity in complex tissue microenvironments

How can computational approaches enhance data interpretation from experiments using MET (Ab-1234) Antibody?

Integrating computational methods with experimental data can provide deeper insights:

• Pathway Modeling:

  • Incorporate quantitative MET activation data into mathematical models

  • Simulate downstream signaling dynamics under various conditions

  • Predict response to combination therapies targeting multiple nodes

• Machine Learning Applications:

  • Develop algorithms to classify cellular responses based on MET signaling patterns

  • Identify subtle signaling signatures associated with specific outcomes

  • Integrate MET data with multi-omics datasets for comprehensive analysis

• Image Analysis Automation:

  • Implement deep learning for automated quantification of immunofluorescence data

  • Develop algorithms for cell-type identification based on MET expression patterns

  • Enable high-throughput analysis of spatial heterogeneity in tissue samples

• Systems Biology Integration:

  • Map MET signaling within the broader cellular interactome

  • Identify context-dependent signaling networks

  • Model feedback and cross-talk mechanisms affecting MET function